Ipsen, a global specialty-driven pharmaceutical company, has reported its fourth quarter and full year results with total sales exceeding €1.1bn in 2011.
The company said in the major Western European countries including Germany and Spain, total group sales accounted to 46.7% at the end of 2011, compared to 50% a year earlier.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
While in other European countries, such as Switzerland, sales amounted to €279.6m in 2011, which is up 8.5% year-on-year excluding foreign exchange impacts.
For the fourth quarter 2011, sales generated in the other European countries reached €68.4m, up 33.4% year-on-year and in major Western European countries amounted to €136.4m, down 1.7% year-on-year.
In 2011, sales generated in North America reached €65.7m, up 15.3% year-on-year, fuelled by the continuous penetration of Somatuline in acromegaly and Dysport in cervical dystonia.
Ipsen’s sales generated in the rest of the world reached €272.5m in 2011, up 15.4% year-on-year, driven by strong volume growth in China, Brazil, Australia and Algeria, and the fourth quarter 2011, sales reached €72.7m, up 38.6% year-on-year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFor the full year 2011, group drug sales increased by 5.7% year-on-year excluding foreign exchange impacts, while consolidated group sales reached €1,159.8m, which is up 5.4% year-on-year excluding foreign exchange impacts.
Ipsen chairman and CEO, Marc de Garidel, said: "With 5.7% up in drug sales, the company has delivered a very strong sales performance, driven by the sustained growth of specialty care, the resilience of primary care in 2011 and also showed 9.9% increase in the very dynamic international drug sales excluding foreign exchange impacts."
Garidel added: "Lastly, Ipsen and Inspiration will work closely together to prepare the launch of Ixinity (IB1001) in Europe. 2012 will be an important transition year to meet the group’s 2020 ambition."
